MRNA
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
Article Summary
BUY- Moderna Inc. (NASDAQ: MRNA) announced that it will host a live conference call and webcast at 8:00 a.m.
- ET on Friday, May 1, 2026 to report its first quarter 2026 financial results and provide a corporate update, with a live webcast available under Events and Presentations in the Investors section of the Moderna website.
- Moderna is a pioneer and leader in the field of mRNA medicine reimagining how medicines are made to transform how we treat and prevent diseases, with its mRNA platform enabling the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
- The archived webcast will be available on Moderna's website approximately two hours after the conference call for one year following the call, with an archived replay of the call available on Moderna's website for a further year.
- Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -39.9% | 25% | 0.0 ptsDeclining (-39.9%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 26.2% | 25% | 80.0 ptsVery Good (26.2%) - Good outlook |
| Target Price Upside ? | 14.5% above | 20% | 0.0 ptsAbove Target (14.5% above) - Target: $45.11 vs Current: $52.78 |
| Gross Margin % ? | 44.3% | 15% | 60.0 ptsSolid (44.3%) - Decent margins |
| Drawdown from 52-Wk High ? | -11.4% | 15% | 40.0 ptsMild Pullback (-11.4%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MRNA
- Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
- The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
- It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
- It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
- The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
- Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.